[go: up one dir, main page]

JPS58144750A - Determination of iron in serum - Google Patents

Determination of iron in serum

Info

Publication number
JPS58144750A
JPS58144750A JP2865882A JP2865882A JPS58144750A JP S58144750 A JPS58144750 A JP S58144750A JP 2865882 A JP2865882 A JP 2865882A JP 2865882 A JP2865882 A JP 2865882A JP S58144750 A JPS58144750 A JP S58144750A
Authority
JP
Japan
Prior art keywords
serum
iron
solution
ascorbic acid
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2865882A
Other languages
Japanese (ja)
Inventor
Tetsuo Tamai
玉井 哲男
Naomi Ito
伊藤 尚美
Mitsuo Ideumi
出海 満男
Masao Kobayashi
木林 昌男
Koichi Hanawa
浩一 花輪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimadzu Corp
Shimazu Seisakusho KK
Original Assignee
Shimadzu Corp
Shimazu Seisakusho KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimadzu Corp, Shimazu Seisakusho KK filed Critical Shimadzu Corp
Priority to JP2865882A priority Critical patent/JPS58144750A/en
Publication of JPS58144750A publication Critical patent/JPS58144750A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

PURPOSE:To achieve an accurate determination of iron in serum by adding a solution of ascorbate oxidase or a solution of oxidizing agent to a serum to measure the absorbancy of a reaction liquid in a reaction treatment of the serum and chromazulol B (CAB). CONSTITUTION:In the treatment of a serum sample with a CAB coloring reagent, a solution of ascorbate oxidase or a solution of oxidizing agent is added to the sample to determine iron in the serum by measuring the absorbancy of the reaction liquid. The oxidizing agent includes patassium folate, sodium folate, etc. The concentration of the oxidizing agent or the ascorbate oxidase added to the reaction liquid is preferably 660mu/l of ascorbate oxidase per 100mg/l of ascorbic acid.

Description

【発明の詳細な説明】 この@明は血清鉄の定量法に関する。[Detailed description of the invention] This @ Ming relates to a method for quantifying serum iron.

血清中の鉄の測定は、溶血性貧血、悪性貧血、再生不良
性貧血、急性肝炎、鉄欠乏性貧血などの検査として臨床
上重要視されている。とくに、最近の医学から、鉄欠乏
性貧血疾患の際に、鉄の生体キレートであるトランスフ
ェリンが増加することが知られておに、血清鉄とともに
、総鉄結合能(?IBO)の測定は、診断上価値が鳥い
・生体内では、食餌として摂取された鉄は、小腸内で吸
収され、腸壁で7ポフエリチンにより 、Fe (1)
から浦に酸化され、フエリチ/と結合し丸形で存在する
。血中に入る際には、Fe CLKR元され、さらに血
中で酸化されFed)と′&)、トランスフェリンとの
結合を行なう。このようにして、吸収され丸鉄は、生体
内のあらゆる場所に送もれ、恒常性を保っている。生体
内の鉄は、ヘモグロビン鉄、建オダロビ/鉄、貯蔵鉄、
血清鉄として存在し、通常、血清鉄の濃度は、成人男子
90〜140μI/di、成人女子80〜120 Il
l/(11である。
Measurement of iron in serum is clinically important as a test for hemolytic anemia, pernicious anemia, aplastic anemia, acute hepatitis, iron deficiency anemia, and the like. In particular, it is known from recent medical science that transferrin, a biological chelate of iron, increases in iron-deficiency anemia diseases. Diagnostic value: In the living body, iron ingested as a diet is absorbed in the small intestine and is converted to Fe(1) by 7 poferritin in the intestinal wall.
It is oxidized to Karaura and exists in a round shape combined with Ferriti/. When it enters the blood, it is converted into Fe CLKR, further oxidized in the blood, and binds to Fed) and '&) and transferrin. In this way, the absorbed round iron is sent to all parts of the body and maintains homeostasis. Iron in the body is hemoglobin iron, Kenodarobi iron, stored iron,
It exists as serum iron, and the normal concentration of serum iron is 90 to 140 μI/di in adult men and 80 to 120 μI/di in adult women.
l/(11.

従来Ojk清鉄測定法には、比色法、原子微光法、発光
法(IOP)、電極法などがある。これらの中“で、自
動生化学分析装置に応用する場合、比色法がもつとも簡
便で、他の生化学分析項目と同様に分析することも可能
で、日常検査には最適である。
Conventional Ojk clear iron measuring methods include colorimetric method, atomic microphotometry, optical emission method (IOP), and electrode method. Among these methods, when applied to automatic biochemical analyzers, the colorimetric method is the simplest and can be analyzed in the same way as other biochemical analysis items, making it ideal for routine testing.

比色法で血清鉄の分析を行なう場合、通常、っぎのよう
な操作が必要である。
When performing serum iron analysis using a colorimetric method, operations such as those described above are usually required.

(1)トランスフェリンから鉄を分離し、除たん白する
(1) Separate iron from transferrin and remove protein.

(2)Fe[)からFe (1)K還ycスル。(2) Fe[) to Fe (1) K-ring yc sul.

f3)Fe(i)を発色させ、測定する。f3) Colorize Fe(i) and measure.

従来法では、(3)の発色剤として、パソ7エナンスロ
リン、トリピリジルトリアジン、フェロジンなどが用い
られてきたが、これらはいずれもFe(1)K対して特
異的に反応するため、上記のような操作が必要であり、
まえ、直接法により測定する場合感度が低いため、微量
血清を用いる最近の自動分析装置では、測定が困難であ
った。
In the conventional method, paso7enanthroline, tripyridyltriazine, ferrozine, etc. have been used as the coloring agent in (3), but since all of these react specifically with Fe(1)K, they cannot be used as described above. operations are required,
Previously, due to the low sensitivity of direct measurements, it was difficult to measure with modern automated analyzers that use trace amounts of serum.

我々は、新しく開発された高感度の鉄キレート発色剤、
クロマズロールB(以下、OABと略す。
We have developed a newly developed highly sensitive iron chelate color former,
Chromazrol B (hereinafter abbreviated as OAB).

図IK構造式を示す)を用いた直接法により、0L−1
2で血清鉄の測定を行なったところ、良好な結果を得た
(島津評論38巻2号27〜3゜頁(1981年怠 し−1ながら、このCABを用いる直接調定法において
も、アスコルビン酸が共存すると鉄の定量に誤差を生じ
、とのアスコルビン酸は輸液された患者中アスコルビン
酸複合剤を投与された患者! にみられるため、従来法では問題があっ九。この発明は
、かかる患者の血清を使用しても、正確にかつ簡便に鉄
含量を定量しうる方法を提供するものである。
0L-1 was obtained by a direct method using
2, serum iron was measured, and good results were obtained (Shimadzu Review Vol. 38, No. 2, pp. 27-3 (1981). The coexistence of ascorbic acid causes errors in the determination of iron, and ascorbic acid is seen in patients who receive infusions and patients who have been administered ascorbic acid complex drugs.Therefore, there are problems with the conventional method. The purpose of the present invention is to provide a method that can accurately and easily quantify iron content even when using blood serum.

そして、この発明による測定法の特徴は、血清とOAB
の反応処理に際し、アスコルビン酸オキシダーゼ溶液ま
たは酸化剤溶液を添加することにある。それによってア
スコルビン酸の負影響が避けられる。
The characteristics of the measurement method according to this invention are that serum and OAB
During the reaction treatment, an ascorbic acid oxidase solution or an oxidizing agent solution is added. The negative effects of ascorbic acid are thereby avoided.

この発明に用いられる酸化剤としては、ヨク酸カリウム
、ヨウ酸ナトリウムなどが挙げられる。
Examples of the oxidizing agent used in this invention include potassium iocate and sodium iorate.

アスコルビン酸オキシダーゼは、市販のものt用いるこ
とができる。これら酸化剤ま九は、アスコルビン酸オキ
シダーゼの反応液中での添加濃度は血清中のアスコルビ
ン酸の濃度によって異なるが。
Commercially available ascorbic acid oxidase can be used. The concentration of these oxidizing agents in the ascorbic acid oxidase reaction solution varies depending on the concentration of ascorbic acid in the serum.

一般にアスコルビンII 100sF//% I 、”
’fスマル(ン酸オキシダーゼ666z/#(好ましい
。この添加濃度において、通常の血清(アスシルピ/酸
複合剤の服用などをしていない患者からの血清)K対し
てもこの発明の定量法は十分適用可能である。
Generally Ascorbine II 100sF//% I,”
'Fsmar(acid oxidase 666z/#) (preferable. At this added concentration, the assay method of the present invention is sufficient even for normal serum (serum from a patient who is not taking an ascilpiate/acid complex) K. Applicable.

この発明において用いるクロマズロールB発色試薬の添
加濃度は、公知の条件を利用すればよい。
The concentration of the chromazurol B coloring reagent used in this invention may be determined using known conditions.

さらに、後述するように、この発明の方法においてはア
スコルビン酸オキシダーゼ溶液または酸化剤溶液と血清
との接触は、一般にクロマズロールB発色試薬と少なく
とも同時かその前が好ましい。詳しくは実験の部で説明
される。
Further, as described below, in the method of the present invention, it is generally preferred that the ascorbic acid oxidase solution or the oxidizing agent solution be brought into contact with the serum at least simultaneously with or before the chromazurol B coloring reagent. Details are explained in the experimental section.

実験の部 1、試薬 クロマズロールBナトリウム塩(株式会社同仁化学研究
所m>。臭化セチルトリメチルアンモニウム(以下OT
MAと略す)、無水酢酸ナトリウム、塩化ナトリウム、
無水酢酸、クエン酸、クエン酸ナトリウム、ヨウ素酸カ
リウム、アスコルビン酸オキシダーゼ(ペーリ/ガーマ
/ハイム社製ビオケンカ)。(いずれも和光特級試薬使
用)。
Experimental part 1, reagent Cromazurol B sodium salt (Dojindo Chemical Laboratory Co., Ltd.). Cetyltrimethylammonium bromide (hereinafter OT)
abbreviated as MA), anhydrous sodium acetate, sodium chloride,
Acetic anhydride, citric acid, sodium citrate, potassium iodate, ascorbic acid oxidase (Biokenka manufactured by Peri/Germa/Heim). (Both use Wako special grade reagents).

2、試薬調整 (a)OAB$11;0AB0.1ftlOOdlxy
ラスコに秤取し、蒸留水で100mとする(2.0mm
ol / l ) (b)O’l’MA溶液:OTMAO,:1t100s
Z/スフラスコに秤取し、蒸留水で100s/とする(
8.2mmol / l )。
2. Reagent adjustment (a) OAB$11; 0AB0.1ftlOOdlxy
Weigh it in a lasco and add distilled water to make it 100m (2.0mm).
ol/l) (b) O'l'MA solution: OTMAO,: 1t100s
Weigh it into a Z/ flask and add distilled water to make it 100s/
8.2 mmol/l).

(0)  酢酸緩衡液;無水酢酸ナトリウム251と、
塩化ナトリウム110fを蒸留水に浴解し、無水酢酸8
.0 m?を加え、全体を1000mとす21(PH4
,7□5)。
(0) Acetic acid buffer; anhydrous sodium acetate 251;
Dissolve 110f of sodium chloride in distilled water, and dissolve 8% of acetic anhydride.
.. 0 m? 21 (PH4
,7□5).

(由発色試薬:OAB溶[60s/KO’l’MA溶液
90gItを加え、混合後、酢酸緩債液を加え、全体を
100011tとする。
(Coloring reagent: Add 90g of OAB solution [60s/KO'l'MA solution, and after mixing, add acetic acid solution to bring the total to 100011t.

(6)  マスク試薬;クエン酸(1水和物)17fと
、クエン酸ナトリウム(2水塩)35Mt−蒸留水で溶
解し100IItとする。
(6) Mask reagent: 17f of citric acid (monohydrate) and 35Mt of sodium citrate (dihydrate) - Dissolved in distilled water to make 100IIt.

検体ブランク測定用発色試薬:発色試薬とマスク試薬を
30:1の割合で混合する。
Coloring reagent for sample blank measurement: Mix coloring reagent and mask reagent at a ratio of 30:1.

(0ヨウ素酸カリウム溶液;ヨウ素酸カリウム0.31
0.015M−リン酸バッファーPH6,8100g/
中に溶解し、反応試薬中濃度0.311Iになるように
調整した。最終反応濃度Fi0.044−とした。
(0 potassium iodate solution; potassium iodate 0.31
0.015M-phosphate buffer PH6, 8100g/
The concentration in the reaction reagent was adjusted to 0.311I. The final reaction concentration Fi was set at 0.044-.

(2)アスコルビン酸オキシダーゼ溶液;アスコルビン
醒オキシダーゼは0.1M−リ/#ナトリウムバッファ
ーpH5,6で希釈し、反応試薬中濃度を666u/l
Kなるように調整した。最終反応濃度は133u/lと
した。
(2) Ascorbic acid oxidase solution; ascorbic acid oxidase was diluted with 0.1 M-Li/# sodium buffer pH 5,6, and the concentration in the reaction reagent was 666 u/l.
I adjusted it so that it was K. The final reaction concentration was 133 u/l.

なお、試薬の調整に用いるガラス器具類は、4〜6N塩
酸に一夜間浸して除鉄し、蒸留水で十分にすすぎ、汚染
されないように注意して乾燥しておく。また調整用の水
も純度の高いイオン交換水か蒸留水を使用する。
Note that the glassware used for preparing the reagents is soaked overnight in 4-6N hydrochloric acid to remove iron, thoroughly rinsed with distilled water, and carefully dried to avoid contamination. Also, use highly purified ion-exchanged water or distilled water for conditioning.

3、装置 島津自動生化学分析装置0L−12形、島津原子吸光/
フレーム分光光度計AA−640−13形を用いた。
3. Equipment Shimadzu automatic biochemical analyzer 0L-12 type, Shimadzu atomic absorption/
A flame spectrophotometer AA-640-13 type was used.

4、分析条件、および操作 0L−12において同時に測定可能な12チヤンネルの
うち、5チヤンネルと9チヤンネルをそれぞれ鉄分折用
、検体ブランク用とした。試薬送液用ディスペンサは、
流路における鉄汚染を避けるため、テフロン材質の電磁
弁が用いられているボ/プを使用し丸。
4. Analysis Conditions and Procedures Of the 12 channels that can be measured simultaneously under 0L-12, channels 5 and 9 were used for iron analysis and as a sample blank, respectively. The dispenser for reagent delivery is
In order to avoid iron contamination in the flow path, a valve with a Teflon material solenoid valve is used.

(1)重版プール血清に所定量のアスコルビン酸を添加
して検体とした(アスコルビン酸の添加量は図1参照)
(1) A predetermined amount of ascorbic acid was added to the reprinted pooled serum to prepare the sample (see Figure 1 for the amount of ascorbic acid added).
.

この血清検体50μノを純水200μmとと−に反応管
に分注する。
50 μm of this serum sample and 200 μm of pure water are dispensed into a reaction tube.

一方アスコルビン酸オキシダーゼ溶液t−第1試薬とし
、この0.3 dを検体分注後15秒後(第2列目)に
分注した。さらに発色試薬(前記2.d)項に記載を第
2試薬とし、その1.5s/l−第1試薬分注後0秒(
同時分注)、30秒(第4列目)、60秒(第6列目)
後に分注した。
On the other hand, ascorbic acid oxidase solution t-1st reagent was used, and 0.3 d of this was dispensed 15 seconds after dispensing the sample (second row). Furthermore, the coloring reagent (2.d) above is described as the second reagent, and its 1.5 s/l - 0 seconds after dispensing the first reagent (
simultaneous dispensing), 30 seconds (4th column), 60 seconds (6th column)
It was later dispensed.

史に、ブランクチャンネルでは上記の第2試薬の分注の
際にマスク試薬を同時分注した。
Historically, in the blank channel, the mask reagent was simultaneously dispensed when the second reagent was dispensed.

(軸)  上ffiのアスコルビン酸オキシダーゼ溶液
の代りに、ヨウ素酸カリウム溶液を第1試薬とし、上記
の(1)と同様に分注した。
(Axis) Instead of the ascorbic acid oxidase solution in the upper ffi, a potassium iodate solution was used as the first reagent and dispensed in the same manner as in (1) above.

(ilil)  IlI光では、発色した溶液の最大吸
収波長は630Imn  −あるが、この−j定では6
28Imと670Imの二波長を用いた。その理由は、
0L−12の検出器の関係と吸収曲線がブロードであり
、また試薬プラ/りの吸光度が大きいために670Im
を対象側波長として選んだ。
(ilil) With IlI light, the maximum absorption wavelength of a colored solution is 630Imn -, but with this -j constant, it is 630Imn -.
Two wavelengths of 28Im and 670Im were used. The reason is,
The detector relationship and absorption curve of 0L-12 are broad, and the absorbance of the reagent plastic is large, so 670 Im
was selected as the target wavelength.

なお、測定データの検体プラ/り補正は、つぎの(1)
式に基づいて自動的に行なわれる。
In addition, the sample value correction of measurement data is as follows (1)
This is done automatically based on the formula.

(1) (!=K・(ムドムtb )−(St/Sl)
・(A!−ム2b))ここで、0:濃度(uf/dl)
、に:1度換算係数、A1:分析用チャンネル測定値、
ムlb ”分析用チャンネル試薬ブランク、ム!:検体
ブランク用チャンネル測定値、ム、b=検体ブランク用
チャンネル試薬ブランク、8!/ 81 :感度比、(
Al、Alb%A!、AteいずれもmAbg単位)キ
ャリフレージョンは市販コ、ントロール血清ハイラント
’l (Lot、No、0368WOOdム)を用いて
行なつ九。濃度Cを208μf/al (デュポンaC
&による測定値)として求めたに値は−2,2101(
μf/dJ−mAbs)であった。
(1) (!=K・(mudomtb)−(St/Sl)
・(A!-mu2b)) Here, 0: Concentration (uf/dl)
, N: 1 degree conversion factor, A1: Analysis channel measurement value,
Mlb "Analysis channel reagent blank, M!: Channel measurement value for sample blank, M, b = Channel reagent blank for sample blank, 8!/81: Sensitivity ratio, (
Al, Alb%A! Calibration was performed using a commercially available control serum Hylant'l (Lot, No. 0368 WOODM). Concentration C is 208 μf/al (Dupont aC
The value obtained as -2,2101 (measured value by &) is -2,2101 (
μf/dJ-mAbs).

5、分析納本 (1)゛  アスコルビン酸オキシダーゼ添加血清検体
を横軸に、Fe測定値を縦軸にとシ、アスコルビン酸の
除去効果を示したのが図1である。
5. Analysis Report (1) Figure 1 shows the ascorbic acid removal effect, with the ascorbic acid oxidase-added serum specimen on the horizontal axis and the Fe measurement value on the vertical axis.

比較のため純水を分注した結果を図1中に破線で示し、
第1試薬と同時に第2試薬を加えた場合、30秒後、1
分後に加えた場合の効果を示しているO 1九、これらの添加条件に対応した同時再塊性のデータ
は表1の通りである。
For comparison, the results of dispensing pure water are shown by the broken line in Figure 1.
If the second reagent is added at the same time as the first reagent, after 30 seconds, 1
Table 1 shows the effect of O 19 when added after 1 minute, and the simultaneous re-agglomeration data corresponding to these addition conditions are shown in Table 1.

表1  同時再現性 (1) 以上の結果から、共存するアスコルビン酸による影響(
測定値への負の影響)を充分除去できることが判明しえ
Table 1 Simultaneous reproducibility (1) From the above results, the influence of coexisting ascorbic acid (
It turns out that the negative influence on measured values can be sufficiently eliminated.

まえ上記の条件で社、第2試薬の分注を第1試薬の分注
後30秒で行うのが最良であることが分る0 (II)  Wつ木酸カリウムの添加 除去効果は図2に示し、同時再現性を表2に示す。
Under the above conditions, it is found that it is best to dispense the second reagent 30 seconds after dispensing the first reagent. Table 2 shows the simultaneous reproducibility.

表2  同時再現性(2) 以上の結果から、ヨウ素酸カリウム添加による共存アス
コルビン酸の負影譬が充分避けられることが明らかであ
るが、上記条件下で社第2試薬の分注は同時あるiは3
0秒後がIIkILであった。
Table 2 Simultaneous reproducibility (2) From the above results, it is clear that the addition of potassium iodate sufficiently avoids the negative effects of coexisting ascorbic acid. i is 3
0 seconds later was IIkIL.

【図面の簡単な説明】[Brief explanation of the drawing]

図1と図2は、血清中におけるアスコルビン酸の共存に
対し、アスコルビン酸オキシダーゼ又は曹つ木酸カリウ
ム添加による鉄含量測定値に対する影響を示す図である
。縦軸は鉄量で、横軸はアスコルビン酸添加量を示す。
FIGS. 1 and 2 are diagrams showing the influence of the addition of ascorbic acid oxidase or potassium sulfate on the measured iron content with respect to the coexistence of ascorbic acid in serum. The vertical axis shows the amount of iron, and the horizontal axis shows the amount of ascorbic acid added.

Claims (1)

【特許請求の範囲】 1、血清試料をクロマズロールB発色試薬で処理する際
に、アスコルビン酸オキシダーゼ溶液またFi酸化剤溶
液を添加し1反応液の吸光度を測定して血清中の鉄分を
定量することよりなる血清鉄の定量法。 2、アスコルビン酸オキシダーゼ溶液または酸化剤溶液
の添加と同時ま九は添加約30#後にクロマズロールB
発色試薬を添加する特許請求の範囲第1項記載の定量法
[Claims] 1. When treating a serum sample with a Cromazurol B coloring reagent, add an ascorbic acid oxidase solution or a Fi oxidizing agent solution, 1. Measure the absorbance of the reaction solution, and quantify the iron content in the serum. A method for quantifying serum iron consisting of: 2. At the same time as adding ascorbic acid oxidase solution or oxidizing agent solution, add Chromazurol B after about 30 minutes of addition.
The quantitative method according to claim 1, wherein a coloring reagent is added.
JP2865882A 1982-02-23 1982-02-23 Determination of iron in serum Pending JPS58144750A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2865882A JPS58144750A (en) 1982-02-23 1982-02-23 Determination of iron in serum

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2865882A JPS58144750A (en) 1982-02-23 1982-02-23 Determination of iron in serum

Publications (1)

Publication Number Publication Date
JPS58144750A true JPS58144750A (en) 1983-08-29

Family

ID=12254599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2865882A Pending JPS58144750A (en) 1982-02-23 1982-02-23 Determination of iron in serum

Country Status (1)

Country Link
JP (1) JPS58144750A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925570A (en) * 1991-12-25 1999-07-20 Iatron Laboratories, Inc. Method of measuring metals in samples of living body
US6627448B1 (en) * 1999-10-04 2003-09-30 Reference Diagnostics, Inc. Analyte-binding assay

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925570A (en) * 1991-12-25 1999-07-20 Iatron Laboratories, Inc. Method of measuring metals in samples of living body
US6627448B1 (en) * 1999-10-04 2003-09-30 Reference Diagnostics, Inc. Analyte-binding assay

Similar Documents

Publication Publication Date Title
Cholak et al. Determination of lead in biological and related material by atomic absorption spectrophotometry
Kessler et al. An automated procedure for the simultaneous determination of calcium and phosphorus
JPH0113062B2 (en)
JPH09511575A (en) Cyanide-free reagents and methods for the determination of hemoglobin
EP1881328A1 (en) Method of determining iron concentration
US5387524A (en) Method for quantitative flow injection analysis of metals in body fluids
US4393142A (en) Assay method and reagent for the determination of chloride
US4105408A (en) Urea assay
JPS58144750A (en) Determination of iron in serum
CA2071001A1 (en) Reagent and methods for serum iron assay
JP3220378B2 (en) Method and reagent for quantification of total protein
US4095948A (en) Determination of uric acid
Moorehead et al. An automated micromethod for determination of serum glucose, with an improved o-toluidine reagent
Klein et al. Application of Fe (II)-5-pyridyl benzodiazepin-2-ones to the determination of serum iron and iron-binding capacity
US6355489B1 (en) Method for the determination of oxygen-centered free radicals
US4826773A (en) Method and reagent for the quantitative determination of phosphorous in serum and urine
US3792044A (en) Method for determining glucose with o-toluidine reagent containing an arsenic compound
Bertrand et al. Determination of serum methemalbumin by second-derivative spectroscopy
Goodwin Direct estimation of serum iron and unsaturated iron binding capacity in a single aliquot
JP2001099826A (en) Complex coloring method and coloring reagent
JP2632989B2 (en) Method for measuring unsaturated iron binding ability
JPH04361160A (en) Measurement of protein
Liu et al. Interference of sodium azide with measurement of serum uric acid by the direct acid ferric reduction procedure.
JPH02122267A (en) Hemoglobin quantitative reagent kit and hemoglobin quantitative method using the same
JP3614951B2 (en) Methods and reagents for measuring enzyme activity